GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Joinn Laboratories (China) Co Ltd (HKSE:06127) » Definitions » Cyclically Adjusted Price-to-FCF

Joinn Laboratories (China) Co (HKSE:06127) Cyclically Adjusted Price-to-FCF : 78.33 (As of Jun. 06, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Joinn Laboratories (China) Co Cyclically Adjusted Price-to-FCF?

As of today (2025-06-06), Joinn Laboratories (China) Co's current share price is HK$14.10. Joinn Laboratories (China) Co's Cyclically Adjusted FCF per Share for the fiscal year that ended in Dec24 was HK$0.18. Joinn Laboratories (China) Co's Cyclically Adjusted Price-to-FCF for today is 78.33.

The historical rank and industry rank for Joinn Laboratories (China) Co's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

HKSE:06127' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 46.33   Med: 67.03   Max: 352.67
Current: 57.61

During the past 13 years, Joinn Laboratories (China) Co's highest Cyclically Adjusted Price-to-FCF was 352.67. The lowest was 46.33. And the median was 67.03.

HKSE:06127's Cyclically Adjusted Price-to-FCF is ranked worse than
77.27% of 66 companies
in the Medical Diagnostics & Research industry
Industry Median: 27.72 vs HKSE:06127: 57.61

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Joinn Laboratories (China) Co's adjusted free cash flow per share data of for the fiscal year that ended in Dec24 was HK$0.100. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is HK$0.18 for the trailing ten years ended in Dec24.

Shiller PE for Stocks: The True Measure of Stock Valuation


Joinn Laboratories (China) Co Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Joinn Laboratories (China) Co's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Joinn Laboratories (China) Co Cyclically Adjusted Price-to-FCF Chart

Joinn Laboratories (China) Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 340.29 149.61 71.15 50.08

Joinn Laboratories (China) Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 50.08 -

Competitive Comparison of Joinn Laboratories (China) Co's Cyclically Adjusted Price-to-FCF

For the Diagnostics & Research subindustry, Joinn Laboratories (China) Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Joinn Laboratories (China) Co's Cyclically Adjusted Price-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Joinn Laboratories (China) Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Joinn Laboratories (China) Co's Cyclically Adjusted Price-to-FCF falls into.


;
;

Joinn Laboratories (China) Co Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Joinn Laboratories (China) Co's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=14.10/0.18
=78.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Joinn Laboratories (China) Co's Cyclically Adjusted FCF per Share for the fiscal year that ended in Dec24 is calculated as:

For example, Joinn Laboratories (China) Co's adjusted Free Cash Flow per Share data for the fiscal year that ended in Dec24 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec24 (Change)*Current CPI (Dec24)
=0.1/114.8925*114.8925
=0.100

Current CPI (Dec24) = 114.8925.

Joinn Laboratories (China) Co Annual Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201512 0.164 100.600 0.187
201612 0.161 102.600 0.180
201712 0.225 104.500 0.247
201812 0.084 106.500 0.091
201912 0.038 111.200 0.039
202012 0.531 111.500 0.547
202112 0.753 113.108 0.765
202212 1.035 115.116 1.033
202312 0.628 114.781 0.629
202412 0.100 114.893 0.100

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Joinn Laboratories (China) Co  (HKSE:06127) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Joinn Laboratories (China) Co Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Joinn Laboratories (China) Co's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Joinn Laboratories (China) Co Business Description

Traded in Other Exchanges
Address
A5 Rongjing East Street, Beijing Economic-Technological Development Area, Beijing, CHN, 100176
Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non-Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.
Executives
Yi Fang Da Ji Jin Guan Li You Xian Gong Si 2102 Investment manager
Futu Trustee Limited 2301 Trustee
Ubs Group Ag 2201 Interest of corporation controlled by you
Aggregate Of Abrdn Plc Affiliated Investment Management Entities 2102 Investment manager
Fil Limited 2201 Interest of corporation controlled by you
Pandanus Associates Inc. 2201 Interest of corporation controlled by you
Pandanus Partners L.p. 2201 Interest of corporation controlled by you
Brown Brothers Harriman & Co. 2502 Approved lending agent
Fidelity Funds 2101 Beneficial owner
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Abrdn Asia Focus Plc 2101 Beneficial owner
Morgan Stanley 2201 Interest of corporation controlled by you
The Goldman Sachs Group, Inc. 2201 Interest of corporation controlled by you
Apg Asset Management N.v. 2101 Beneficial owner
Apg Groep N.v. 2101 Beneficial owner

Joinn Laboratories (China) Co Headlines

No Headlines